ITOS - iTeos Therapeutics, Inc. Stock Price, Fair Value and News

$7.42+0.20 (+2.77%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ITOS Price Action

Last 7 days

-3.4%

Last 30 days

-5.5%

Last 90 days

-34.1%

Trailing 12 Months

-28.8%

ITOS RSI Chart

ITOS Valuation

Market Cap

271.1M

Price/Earnings (Trailing)

-2.24

Price/Sales (Trailing)

7.75

EV/EBITDA

-1.33

Price/Free Cashflow

-2.25

ITOS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ITOS Fundamentals

ITOS Revenue

Revenue (TTM)

35.0M

Rev. Growth (Qtr)

-100%

ITOS Earnings

Earnings (TTM)

-121.3M

Earnings Growth (Yr)

-40.68%

Earnings Growth (Qtr)

-536.34%

ITOS Profitability

EBT Margin

-320.49%

Return on Equity

-19.19%

Return on Assets

-16.77%

Free Cashflow Yield

-44.39%

ITOS Investor Care

Shares Dilution (1Y)

2.09%

Diluted EPS (TTM)

-3.15

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	35.0M	35.0M	0
2023	127.7M	86.0M	66.5M	12.6M
2022	500.0M	539.0M	454.2M	267.6M
2021	9.0M	10.6M	112.6M	352.4M
2020	4.4M	4.8M	5.2M	5.6M
2019	0	0	0	4.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About iTeos Therapeutics, Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Michel Detheux Ph.D.
WEBSITE	iteostherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	125

iTeos Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for iTeos Therapeutics, Inc.? What does ITOS stand for in stocks?

ITOS is the stock ticker symbol of iTeos Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iTeos Therapeutics, Inc. (ITOS)?

As of Fri Dec 20 2024, market cap of iTeos Therapeutics, Inc. is 271.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ITOS stock?

You can check ITOS's fair value in chart for subscribers.

Is iTeos Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ITOS is over valued or under valued. Whether iTeos Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact iTeos Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITOS.

What is iTeos Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ITOS's PE ratio (Price to Earnings) is -2.24 and Price to Sales (PS) ratio is 7.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITOS PE ratio will change depending on the future growth rate expectations of investors.